Patents by Inventor Lisa D. Pfefferle

Lisa D. Pfefferle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carbon nanotube compositions and methods of use thereof
    Patent number: 10485856
    Abstract: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: November 26, 2019
    Assignee: Yale University
    Inventors: Tarek M. Fahmy, Lisa D. Pfefferle, Gary L. Haller, Tarek R. Fadel
  • Carbon nanotube compositions and methods of use thereof
    Patent number: 9737593
    Abstract: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 22, 2017
    Assignee: Yale University
    Inventors: Tarek M. Fahmy, Lisa D. Pfefferle, Gary L. Haller
  • Carbon Nanotube Compositions and Methods of Use Thereof
    Publication number: 20170209570
    Abstract: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.
    Type: Application
    Filed: March 17, 2017
    Publication date: July 27, 2017
    Inventors: Tarek M. Fahmy, Lisa D. Pfefferle, Gary L. Haller
  • CARBON NANOTUBE COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160213761
    Abstract: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.
    Type: Application
    Filed: April 5, 2016
    Publication date: July 28, 2016
    Inventors: Tarek M. Fahmy, Lisa D. Pfefferle, Gary L. Haller
  • Carbon nanotube compositions and methods of use thereof
    Patent number: 8658178
    Abstract: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: February 25, 2014
    Assignee: Yale University
    Inventors: Tarek M. Fahmy, Lisa D. Pfefferle, Gary L. Haller
  • CARBON NANOTUBE COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20110014217
    Abstract: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.
    Type: Application
    Filed: March 19, 2009
    Publication date: January 20, 2011
    Inventors: Tarek M. Fahmy, Lisa D. Pfefferle, Gary L. Haller